FDA-approved exoskeletons are currently uncommon and confined to treating particular ailments. Ekso Bionics gained approval to commercialise their EksoNR device for multiple sclerosis rehab in June. Wandercraft’s clearance makes the technology available to a broader spectrum of patients, which may be particularly beneficial given that strokes are a leading cause of long-term impairment in the United States. Every year, around 795,000 individuals in the United States have a stroke; this might help some of them recover their mobility.
